Navigating Due Diligence and the Long Game

Transcript

SPEAKER_1: Let's dive into what happens after your pitch lands, focusing on the due diligence process specific to health tech startups. Due diligence in health tech involves unique challenges beyond standard tech diligence. SPEAKER_2: Not even close. Standard diligence covers team, product-market fit, market size, traction, and legal risk. Health tech keeps all of that and adds clinical evidence, data privacy, cybersecurity, quality management, and regulatory compliance. Each one can independently kill a deal. SPEAKER_1: So what's the clean framework for those extra layers? Is there a way to organize them? SPEAKER_2: regulatory compliance, data protection, reimbursement strategies, and intellectual property. Investors assess FDA oversight, data governance, reimbursement potential, and IP defensibility. Miss any one and the round stalls. SPEAKER_1: The regulatory piece seems like the one founders most underestimate. Why does it carry so much weight? SPEAKER_2: Because it determines the entire business model. Investors check whether the product qualifies as a medical device or software-as-a-medical-device. For AI-based clinical tools, some investors now hire external regulatory experts just for this review. That's not routine — that signals how seriously they treat the risk. SPEAKER_1: And data protection — is that mostly a compliance checkbox, or can it actually kill a deal? SPEAKER_2: It can be a deal-breaker. Health data is among the most sensitive data that exists. Weak data governance signals operational immaturity to institutional investors. A startup with strong clinical results but weak data governance can still hit a deal-breaking issue late in diligence. SPEAKER_1: That's a brutal place to lose a deal. Now, how long does all of this actually take? Because timeline matters enormously for runway planning. SPEAKER_2: It scales with round size. Later-stage health tech rounds can involve technical audits, regulatory reviews, and quality audits running several weeks to months. Research also shows CEOs spend a substantial portion of their time on capital raising during active rounds — time not spent on product or customers. The operational cost is real. SPEAKER_1: So the data room becomes critical just to keep that timeline from dragging. What actually goes in a well-built one? SPEAKER_2: Corporate structure, cap table, financials, contracts, product documentation, and regulatory filings — all organized and current. A clean data room materially accelerates diligence and reduces friction in negotiations. The key idea is that gaps in the data room signal gaps in the business itself. SPEAKER_1: The cap table piece can get complicated fast — especially with SAFEs and convertible notes at early stages. SPEAKER_2: That's a real friction point. Convertible securities make cap tables genuinely hard to interpret until conversion terms are fully modeled. Later-round investors scrutinize this carefully. Founders who haven't kept clean records of financing documents and cap table changes will slow their own diligence down. SPEAKER_1: Now, there's a concept called reverse due diligence. What does that actually mean in practice? SPEAKER_2: Some experienced VCs actively encourage founders to investigate them back — track record, governance style, how they behave when things go sideways. Misaligned expectations between founders and investors are a documented cause of later conflict. The capital is only part of what an investor brings. The governance relationship lasts years. SPEAKER_1: And investors aren't evaluating just this round in isolation — they're modeling the whole financing journey. SPEAKER_2: Exactly. Investors frequently model multiple rounds — estimating dilution, capital needs, and expected time to exit. That means the product roadmap has to align with evolving regulation, reimbursement frameworks, and clinical guidelines over time. Policy changes can materially affect whether a digital health business model survives. That's the long game. SPEAKER_1: So for Anvesha and everyone building in this space — what's the single most important thing to internalize about due diligence? SPEAKER_2: it's not the finish line. A term sheet is a non-binding document. The real commitment comes after diligence closes and definitive agreements are signed. The startups that move through fastest are the ones who treated diligence as a continuous process — building the data room, maintaining clinical evidence, keeping regulatory filings current — long before any investor asked.